Type 2 Diabetes

26 weeks of treatment with empagliflozin reduced the myocardial glucose metabolic rate by 45.1% in patients with type 2 diabetes.

Gary Scheiner, MS, CDE, discusses updates in diabetes technologies from the ADCES annual meeting, the role of CDES in optimizing uptake and use of new technology, and the ADCES's push to advance diabetes management.

In this episode, the hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down with ADCES 2022 Diabetes Care and Education Specialist of the Year Anastasia Albanese-O’Neill, PhD, to discuss her inspiration, her work within the field, and insight into the project she has decided to focus on during her year as ADCES Diabetes Care and Education Specialist of the Year.

Gary Scheiner, MS, CDE, discusses themes and topics of discussion at ADCES 22.

In this special edition ADCES 22 episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by David Walton, CEO of the T1D Exchange, who takes our hosts on a deep dive into the history of the organization, what it is doing right now to improve patient care, and how it expects to grow and improve management of type 1 diabetes into the future.

In this special edition of Diabetes Dialogue recorded on-site at ADCES 22, our hosts are joined by Korey Hood, PhD, a staff psychologist and professor at Stanford University. Founder of DiabetesWise and DiabetesWisePro, Hood talks to Diana Isaacs, PharmD, and Natalie Bellini, DNP, about his efforts and how the online resources are pushing care forward.

After leading a session on the topic at ADCES, Sara Reece, PharmD, sat down to discuss the latest updates in chronic kidney disease management among patients with type 2 diabetes.

Scott Kahan, MD, MPH, discusses the concept of weight stigma, its historical impact, and avenues for confronting weight stigma that currently exists in clinical care settings.

A study presented at ADCES 22 details opinions of certified diabetes care and education specialists toward the POGO Automatic blood glucose monitoring system.

A presentation by Christine Schumacher, PharmD, and Elizabeth Van Dril, PharmD, at ADCES examines the current state of heart failure management in patients with diabetes.

Called the DiaBeats algorithm, new research suggests leveraging the machine learning-based algorithm, combined with ECG recordings, could help predict increased risk of developing prediabetes and type 2 diabetes.

New research suggests there was a 53% greater 5-year risk of cardiovascular disease in men with type 2 diabetes who received a GnRH agonist for prostate cancer compared with their counterparts who did not receive GnRH agonists.

The screening of more than 50,000 youth patients in diverse populations of Colorado and Bavaria, Germany reported no association between infection and T1D.

Data from a 14-week randomized clinical trial suggests adherence to a time-restricted diet was associated with significant differences in weight loss and improvements in blood pressure compared to a typical diet.

Dr. Gregory Weiss provides perspective on a recent study examining associations between serum ceramide levels and the likelihood of achieving normoglycemia among patients who have undergone RYGB.

An analysis of more than 20 years of follow-up data from more than 4000 patients in the Malmö Diet and Cancer Study shed light on associations between prostasin concentrations and risk of developing diabetes and cancer mortality.

A retrospective study provides insight into the ability of CGM technology to improve glycemic control in in-hospital settings and, potentially, reduce the risk of spreading infectious diseases.

Our endocrinology month in review spotlights the most popular content from the past month. The top content from July includes hormone therapy guidance from NAMS, a comparison of management practices among Medicare beneficiaries, and a recap of the top approvals from the first half of 2022.

The highest adjusted probability of CGM use occurred in middle adulthood, while the probability of CGM utilization decreased with increasing age in older adulthood.

For the July 2022 episode of Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to provide perspective on the latest advances in the fight to cure type 1 diabetes and offer insight into their experiences at the Practical Ways to Achieve Targets in Diabetes Care Conference held in Keystone, CO in mid-July.

An analysis of the DCCT and EDIC studies provides clinicians with insights into the risk factors associated with incident cancer diagnoses among patients with type 1 diabetes, suggesting those using higher daily doses of insulin had a more than 4-fold increase in risk of a cancer diagnosis.

New data report a slightly higher but nonsignificant increase in diabetes incidence among children in Canada during COVID-19 pandemic.

The new recommendation acknowledges the role of disease-preventive behaviors that can be taken on by approximately 12% of the US population.

A randomized crossover trial assessing the effects of a 3-week time-restricted eating regimen details the impact of the approach on time in range and other glycemic measures among adults with type 2 diabetes.

Jennifer Green, MD, discusses the benefit of relatively new innovations including continuous glucose monitoring and smart insulin pens.

Data from a major trial detail the cardiorenal benefits of dapagliflozin use among patients with type 2 diabetes based on use of background cardiovascular medications.

Our latest case report from Brady Pregerson, MD, features a man in his 30s with a history of type 1 diabetes mellitus on insulin presenting to the emergency department for left index finger pain and swelling. Can you determine the correct diagnosis?

During follow-up, 2.6% of the patients were diagnosed with depression, while 32.1% were treated with antidepressants.

The Duke expert reviews key strategies for starting and continuing care with the pivotal glycemic control agent.

An analysis of data from more than 450,000 patients in the UK details an 81% increase in the net incidence of diabetes in the first 4 weeks after contracting COVID-19, which remained elevated through weeks 5-12, compared to those who did not contract COVID-19.